ReviewCureus2025
The Immunoglobulin A Nephropathy Renaissance: From Pathogenesis to Personalized Therapy.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Minimal Change Disease With Mesangial IgA Deposition: A Clinicopathological Case Series From a Tunisian Referral Center.Case reports in nephrology · 2026Article
- Precision targeting of gut-kidney axis: mucosal immunomodulation in IgA nephropathy-a perspective.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage renal failure. Its clinical spectrum ranges from asymptomatic microscopic hematuria to nephrotic syndrome and rapidly progressive glomerulonephritis. Advances in understanding the "multi-hit" pathogenesis of IgAN, along with epidemiologic and genetic studies revealing striking ethnic variation, have shifted management from nonspecific supportive measures toward targeted therapies. The purpose is to summarize current paradigms in IgAN, focusing on evolving pathophysiology, biomarkers, risk stratification, and emerging targeted therapies that can improve personalized management and long-term renal outcomes. This narrative review synthesizes recent literature on IgAN, including traditional and emerging biomarkers (e.g., proteinuria, eGFR, Oxford MEST-C features, persistent hematuria, complement activation products, C4d staining, urinary CD163, and galactose-deficient IgA1 assays) and novel therapeutic approaches targeting mucosal immunity, B-cell signaling, complement pathways, and pharmacologic agents such as SGLT2 inhibitors, endothelin receptor antagonists, and targeted-release corticosteroids. Emerging biomarkers and targeted therapies in IgAN offer the potential for improved risk stratification and personalized treatment, moving beyond supportive care to optimize long-term renal outcomes. In this narrative review, we provide a comprehensive overview of IgAN, focusing on contemporary management. We highlight recent advances in biomarkers and treatment paradigms, including novel therapies, and discuss current and emerging therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.